Vitamin E Treatment for Tardive Dyskinesia
Open Access
- 1 September 1999
- journal article
- clinical trial
- Published by American Medical Association (AMA) in Archives of General Psychiatry
- Vol. 56 (9) , 836-841
- https://doi.org/10.1001/archpsyc.56.9.836
Abstract
TARDIVE dyskinesia (TD) is a frequent side effect of treatment with neuroleptic drugs. The syndrome is persistent, often irreversible, and characterized by abnormal movements including lingual and orofacial dyskinesia, grimacing, tics, choreic movements, athetosis, and dystonia. Overall prevalence is 15% to 25% of subjects treated with neuroleptics, with increased risk associated with aging and nonschizophrenic disorders.1-4 There is no established treatment for TD.Keywords
This publication has 11 references indexed in Scilit:
- Re: Factors Associated with Specific Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Sexual Dysfunctions in Breast Cancer Survivors: A Study of Patients and Their PartnersJournal of Urology, 2018
- Long-term treatment effects of vitamin E for tardive dyskinesiaBiological Psychiatry, 1998
- Reliability of an instrumental assessment of tardive dyskinesia: results from VA Cooperative Study #394.Psychopharmacology, 1997
- Antioxidant treatment of tardive dyskinesiaProstaglandins, Leukotrienes & Essential Fatty Acids, 1996
- Gender Differences in Tardive Dyskinesia: A Critical Review of the LiteratureSchizophrenia Bulletin, 1992
- Oxygen Radicals and Neuropsychiatric IllnessArchives of General Psychiatry, 1991
- A Rating Scale for Drug-Induced AkathisiaThe British Journal of Psychiatry, 1989
- Adaptive allocation in randomized controlled trialsControlled Clinical Trials, 1985
- Effect of chlorpromazine on central nervous system concentrations of manganese, iron, and copperLife Sciences, 1977
- A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTSActa Psychiatrica Scandinavica, 1970